On January 25, 2022 Personal Genome Diagnostics Inc. (PGDx), a leader in cancer genomics, reported an update to the Proprietary Laboratory Analyses (PLA) code for its comprehensive genomic profiling test, PGDx elio tissue complete (Press release, Personal Genome Diagnostics, JAN 25, 2022, View Source [SID1234606784]). The Centers for Medicare & Medicaid Services (CMS) finalized a national reimbursement rate of $2,919.60 for the PLA code (0250U) that PGDx obtained for the test.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are thrilled that CMS has responded to PGDx’s advocacy efforts, agreeing with our crosswalk recommendation for the previously obtained PLA code," said PGDx CEO Megan Bailey. "The PGDx elio tissue complete test enables rapid and actionable genomic insights for patients living with advanced cancers, and the national reimbursement rate as determined by CMS will allow for more patients to receive targeted insights and informed treatment options that could improve outcomes."

The new Medicare payment rate went into effect on January 1, 2022. More information can be found in the latest Medicare Clinical Laboratory Fee Schedule Files.

The PGDx elio tissue complete solution is an in-house comprehensive genomic profiling (CGP) test that identifies key genomic alterations and guideline supported biomarkers in solid tumors using a 500+ gene panel. PGDx elio tissue complete is the industry’s first and only NGS diagnostic kit for comprehensive tumor profiling that is FDA cleared and CE-IVD marked for use in labs worldwide.